209 related articles for article (PubMed ID: 21651493)
1. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors.
Cirillo D; Pentimalli F; Giordano A
Curr Med Chem; 2011; 18(19):2854-66. PubMed ID: 21651493
[TBL] [Abstract][Full Text] [Related]
2. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
3. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
5. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
[TBL] [Abstract][Full Text] [Related]
6. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
9. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule degraders of cyclin-dependent kinase protein: a review.
Yu B; Du Z; Zhang Y; Li Z; Bian J
Future Med Chem; 2022 Jan; 14(3):167-185. PubMed ID: 34939427
[TBL] [Abstract][Full Text] [Related]
11. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.
Węsierska-Gądek J; Maurer M
Curr Pharm Des; 2011; 17(3):256-71. PubMed ID: 21348827
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development.
Waters NC; Geyer JA
Expert Opin Ther Targets; 2003 Feb; 7(1):7-17. PubMed ID: 12556199
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division.
Lacy ER; Wang Y; Post J; Nourse A; Webb W; Mapelli M; Musacchio A; Siuzdak G; Kriwacki RW
J Mol Biol; 2005 Jun; 349(4):764-73. PubMed ID: 15890360
[TBL] [Abstract][Full Text] [Related]
14. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
15. Cyclin dependent kinases in cancer: potential for therapeutic intervention.
Canavese M; Santo L; Raje N
Cancer Biol Ther; 2012 May; 13(7):451-7. PubMed ID: 22361734
[TBL] [Abstract][Full Text] [Related]
16. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
McInnes C; Andrews MJ; Zheleva DI; Lane DP; Fischer PM
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):57-69. PubMed ID: 12678915
[TBL] [Abstract][Full Text] [Related]
17. Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Cheng W; Yang Z; Wang S; Li Y; Wei H; Tian X; Kan Q
Eur J Med Chem; 2019 Feb; 164():615-639. PubMed ID: 30639897
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
19. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
[TBL] [Abstract][Full Text] [Related]
20. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
